Overlapping toxicities of anti-tuberculosis drugs and ARV.

<p>Overlapping toxicities of anti-tuberculosis drugs and ARV.</p

Association predictors and death, cure, culture conversion, and smear conversion.

1<p>Adjusted for TB resistance pattern as indicator variables.</p>2<p>Adjustment not possible because less than 6 patients with ODR and none with XDR.</p

Details of included studies.

1<p>Data from routine TB surveillance system of the TB Division State of Sao Paulo identified through 2003 thereby representing a larger study population than those included in the referenced abstracts.</p>2<p>Nested in larger cohort study, which is the design from which we pulled data.</p>3<p>Cure, culture and smear conversion data not presented in publication.</p

Kaplan Meier Curve for cure comparing ART vs. no ART among all-patients (N = 216).

<p><i>Note: 1 additional cure event occurred at month 60</i>.</p

Flow diagram for study inclusion.

<p>Two authors each sent data that was represented by two included studies, therefore 12 references actually included. ¹ Lew W, Pai M, Oxlade O, Martin D and Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008;149:123–34. ² Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009; 6:e1000150. <b>Reasons for Exclusion II.</b> Inappropriate study design (n = 34); Outcomes of interest are not measured (n = 22); Not deemed research/no data collected (n = 18); No TB drug resistance or drug resistance testing (n = 21); No HIV+ patients or HIV-testing (n = 37); No TB-infected patients or TB treatment (n = 4); No 2^nd line drug TB therapy used (n = 16); No ART data collected (n = 3); Author contacted for another study/same patients (n = 12). <b>Other Reasons for Exclusion III (other n = 11):</b> Not interested (n = 1); Inappropriate study design (n = 1); No HIV (n = 3); In process of publication (n = 1); Already contacted (n = 5).</p

Patient characteristics by ART use.

1<p>N's may not add up to total N because of missing values.</p>2<p><i>p</i>-values of ART use vs. non-use comparisons based on the categorical version of variable are presented unless interpretation of p-value based on of continuous version differed.</p>3<p>Effective drug: Demonstrated susceptibility to drug by sputum culture.</p

Effect of previous treatment on association of number of likely effective drugs with treatment success—during different phases of treatment.

<p>Likely effective, drugs to which isolate susceptible in laboratory testing. <i>n</i>, number of patients in subgroup of interest. aOR, adjustment described in footnotes for <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001300#pmed-1001300-t003" target="_blank">Table 3</a>. Success, defined as cure or treatment completion; see Methods for definitions. Initial intensive phase, period when injectable given. Continuation phase, period when no injectable given. Only 18 studies provided information regarding drug susceptibility testing and the number of drugs in the initial phase, while only 15 of these described the number of drugs in the continuation phase. Bold, estimates are significantly different from the reference group.</p

Association of treatment success with duration (adjusted odds and upper bound of CI shown).

<p>(A) Duration of initial intensive phase in all patients (reference group 1.0–2.5 mo). (B) Duration of initial intensive phase—restricted to patients not previously treated with second-line drugs (reference group 1.0–2.5 mo). (C) Total duration of therapy in all patients (reference group is 6.0–12.5 mo). Patients receiving therapy for less than 6 or more than 36 mo excluded from analysis. Note: For duration of 24.6–27.5 mo the upper limit of the CI was 30.2. This is truncated at 21. (D) Total duration of therapy—analysis restricted to patients not previously treated with second-line drugs (reference group is 6.0–12.5 mo. Patients receiving therapy for less than 6 or more than 36 mo excluded from analysis). Note: For duration of 24.6–27.5 mo, the upper limit of the CI was 56.5. This is truncated at 21.</p

'Iter Lapponicum'

<p>Crude treatment success versus failure or relapse or death by study with exact 95% CI, as well as number of subjects with success and number of subjects treated. Fixed and der Simonian and Laird random effects pooled estimates are given (purple dots). Two studies that used only first-line TB drugs are indicated by a red square.</p

Study selection.

<p>Study selection.</p